Translating breakthrough science into breakthrough therapeutics

Investors

ASX Annoucements

05/12/2019 Drug Delivery Greater Than 100% More Effective - Amended

02/12/2019 Change in substantial holding

02/12/2019 Change in substantial holding

02/12/2019 Change in Director's Interest Notices x 2

02/12/2019 Drug Delivery Greater Than 100%

29/11/2019 Appendix 3B

27/11/2019 - CHANGE IN SUBSTANTIAL HOLDING

19/11/2019 - 2019 AGM Chairman's Address

19/11/2019 - 2019 AGM Presentation

19/11/2019 - Completion of Retail Entitlement Offer

16/11/2019 - Conclusion of Genentech Antimicrobial Collaboration

14/11/2019 - PYC INCREASES SHAREHOLDING IN VISION PHARMA

12/11/2019 - CHANGE OF DIRECTOR'S INTEREST NOTICE

12/11/2019 - Change in substantial holding

11/11/2019 - Change in substantial holding

31/10/2019 - ENTITLEMENT OFFER - INVESTOR PRESENTATION

31/10/2019 - Notice Under Section 708AA

31/10/2019 - Appendix 3B

31/10/2019 - $26.8M Fully Underwritten Accelerated Entitlement Offer

31/10/2019 - Trading Halt

30/10/2019 - Quarterly Shareholder Update and Appendix 4C

21/10/2019 - Corporate Governance Statement

18/10/2019 - Appendix 4G

18/10/2019 - Annual Report to Shareholders

18/10/2019 - Notice of Annual General Meeting / Proxy Form

15/10/2019 - Investor Relations Presentation

14/10/2019 - Presentation Oligonucleotide Therapeutics Society Meeting

09/10/2019 - Successful Major Milestone - Human Retina in a Dish Model

01/10/2019 - Strategic Partnership and Lead Program

30/09/2019 - Trading Halt

25/09/2019 - Successful Time-Course Studies in Animals

17/09/2019 - Full Year Statutory Accounts

13/09/2019 - Scientific Advisory Board Appointment

04/09/2019 - Investor Relations Presentation

03/09/2019 - Successful Competitive Drug Evaluation in Animals

30/08/2019 - Preliminary Final Report

23/08/2019 - Investor Call

22/08/2019 - Successful Time - Course Studies in Animals

09/08/2019 - Company Re-branding

07/08/2019 - Response to ASX Aware Query

06/08/2019 - Phylogica's Technology is Effective in Human Cells

24/07/2019 - Company Presentation - July 2019

23/07/2019 - Operational Update and Appendix 4C

23/07/2019 - Animal Models - 400% Outperformance of Gold Standard

27/06/2019 - Break Through Animal Model Results

29/04/2019 - March 2019 Quarterly Operational Update

24/04/2019 - Change of Director's Interest Notice

22/03/2019 - Scientific Advisory Board Appointment

Financial and annual reports

18/10/2019 - Annual Report

30/06/2018 - Annual Report

Media Release

2019 OTS Conference PYC Poster

2019 OTS Conference Janya Grainok (PYC Collaborator) Poster

03/10/2019 - Media Release

Corporate Governance

Phylogica Limited (“Company”) has adopted a Corporate Governance Plan which forms the basis of a comprehensive system of control and accountability for the administration of corporate governance.

The Board is committed to administering the policies and procedures with openness and integrity, pursuing the true spirit of corporate governance commensurate with the Company’s needs.

To the extent they are applicable to the Company, the Board has adopted the ASX Corporate Governance Council’s Corporate Governance Principles and Recommendations 3rd Edition (“Principles & Recommendations”).

A Corporate Governance Statement sets out details of the Company’s compliance with the Principles & Recommendations. Click here to read the ASX Corporate Governance Principles & Recommendations.

The Company is pleased to make the following information on its corporate governance practices available on this website.

Charters

Board

Audit Committee

Risk Committee

Nomination Committee

Remuneration Committee

Policies & Procedures

Corporate Code of Conduct

Disclosure - Performance Evaluation

Disclosure - Continuous Disclosure

Disclosure - Risk Management

Trading Policy

Diversity Poilicy

Shareholder Communication Strategy

Definition of Independence

Appendix 4G